Arbele Advances AI-Powered Cancer Therapies Through Key Collaborations

Arbele, a leading biopharmaceutical and biotechnology innovator specializing in targeting cadherin-17 (CDH17), has announced strategic collaborations to drive advancements in precision oncology through the use of artificial intelligence (AI). These partnerships aim to enhance targeted immunotherapies, specifically bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). The goal is to improve the quantification and prognostic prediction of CDH17 expression in tumor tissue and the surrounding immune microenvironment, accelerating the development of companion diagnostics and clinical trials for advanced cancer patients.

Collaboration with BioAI: Developing an IHC-Based Quantification Algorithm
Arbele has partnered with BioAI Health to create a prototype immunohistochemistry (IHC)-based quantification algorithm. Using the PredictX platform, AI models will be developed based on Arbele’s colorectal cancer (CRC) clinical trial data. The collaboration aims to establish a gold-standard companion diagnostic test for anti-CDH17 therapies, helping select patients and predict clinical outcomes.

Thomas Colarusso, CEO of BioAI, expressed excitement about applying their AI platform to accelerate innovative treatments for gastrointestinal cancers. Dr. John Luk, CEO of Arbele, highlighted that BioAI’s machine learning capabilities will transform how biomarkers are identified, enabling better treatment options for patients with high-mortality cancers.

Collaboration with Chime Biologics: Accelerating CMC Process Development for ADCs and TCEs
Arbele has also formed a partnership with Chime Biologics to fast-track the chemistry, manufacturing, and control (CMC) process development for novel ADCs and TCEs. This collaboration will support the development of around 10 immunotherapeutics pipelines, ensuring the continuous advancement of new molecular entities (NMEs) for investigational new drug (IND) applications over the next five years. The first project, anti-CDH17 ADC (ARB102A), is scheduled for IND submission in early 2025.

Dr. Jimmy Wei, President of Chime Biologics, emphasized their long-standing partnership with Arbele and commitment to delivering innovative immunotherapies through their advanced biologics development and Quality-by-Design (QbD) strategy, improving global access to these treatments.